Venture Funding Deals, July – August 2016

 
• By Deanna Kamienski, Beth Allan, Maureen Riordan, Steven Muntner, and Amanda Micklus
  
Generate a summary of this article
Listen to this article
Beta

Ambrx, Arcus, Cleave Biosciences, InflaRx, MonoSol Rx, Nevakar and Tioma Therapeutics were among firms raising more than $30m in venture funding in July and August. Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive review of emerging biopharmaceutical companies that have received venture funding during the past two months.

Coins

Ambrx Inc. (protein therapeutics known as bio-conjugates) raised $45m in a late-stage financing round led by Apricot Capital and Northeast Securities Prosperity Healthcare Fund. (Also see "VC Roundup: Cleave Raises $37m To Maintain Phase I Momentum, Plus $233.5m In Recent Financings" - Scrip, 10 August, 2016.) Sinopharm Capital, Humanwell Healthcare Fund, and existing investors Fosun Pharma, HOPU Investments, and Everbright Limited Healthcare Fund also participated. The company will use the funds to further develop its Phase I asset ARX788 along with its pipeline of ADC candidates and lead immuno-oncology program CD3-folate. After withdrawing from its planned IPO in June 2014, the company was acquired by a consortium consisting of entities affiliated with Shanghai Fosun Pharmaceutical Group Co. Ltd., HOPU Investments, China Everbright Ltd.'s CEL Healthcare Fund, and WuXi PharmaTech Inc. (Aug.) [See Deal]

Arcus Biosciences Inc. (immuno-oncology) raised $70m through its oversubscribed Series B round. The company's initial targeted amount was $50m....

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

Test Roche Head Of Pharma Strategy Karsten Jung On Rebuilding The Portfolio

 
• By Jessica Merrill

The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Reed Miller

In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab.

Article Without An Author Listed

Here is a short description.

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.